Two Sigma Advisers LP Trims Stock Holdings in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM)

Two Sigma Advisers LP trimmed its position in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) by 15.1% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 174,400 shares of the company’s stock after selling 31,100 shares during the quarter. Two Sigma Advisers LP owned 0.36% of Mirum Pharmaceuticals worth $7,211,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Jones Financial Companies Lllp raised its stake in shares of Mirum Pharmaceuticals by 100.0% in the fourth quarter. Jones Financial Companies Lllp now owns 714 shares of the company’s stock worth $30,000 after purchasing an additional 357 shares during the last quarter. Point72 Asia Singapore Pte. Ltd. purchased a new stake in shares of Mirum Pharmaceuticals during the fourth quarter worth about $35,000. R Squared Ltd acquired a new position in shares of Mirum Pharmaceuticals during the fourth quarter valued at approximately $69,000. AlphaQuest LLC lifted its holdings in Mirum Pharmaceuticals by 969.6% in the 4th quarter. AlphaQuest LLC now owns 1,829 shares of the company’s stock valued at $76,000 after purchasing an additional 1,658 shares in the last quarter. Finally, Summit Investment Advisors Inc. lifted its stake in shares of Mirum Pharmaceuticals by 8.1% in the fourth quarter. Summit Investment Advisors Inc. now owns 4,155 shares of the company’s stock worth $172,000 after buying an additional 312 shares in the last quarter.

Mirum Pharmaceuticals Trading Down 0.1%

MIRM opened at $44.00 on Friday. The company has a debt-to-equity ratio of 1.33, a quick ratio of 3.15 and a current ratio of 3.34. Mirum Pharmaceuticals, Inc. has a one year low of $23.83 and a one year high of $54.23. The company has a market cap of $2.18 billion, a P/E ratio of -21.78 and a beta of 0.95. The business’s 50-day simple moving average is $42.95 and its 200-day simple moving average is $44.59.

Mirum Pharmaceuticals (NASDAQ:MIRM) last announced its quarterly earnings results on Wednesday, May 14th. The company reported ($0.30) EPS for the quarter, beating the consensus estimate of ($0.35) by $0.05. Mirum Pharmaceuticals had a negative net margin of 31.69% and a negative return on equity of 41.22%. The company had revenue of $111.59 million for the quarter, compared to analyst estimates of $98.47 million. During the same period in the prior year, the firm posted ($0.54) earnings per share. The firm’s revenue was up 61.2% on a year-over-year basis. As a group, equities research analysts expect that Mirum Pharmaceuticals, Inc. will post -1.43 EPS for the current fiscal year.

Insider Activity at Mirum Pharmaceuticals

In other Mirum Pharmaceuticals news, CEO Christopher Peetz sold 27,279 shares of the firm’s stock in a transaction on Monday, March 17th. The shares were sold at an average price of $44.21, for a total transaction of $1,206,004.59. Following the transaction, the chief executive officer now directly owns 138,641 shares of the company’s stock, valued at approximately $6,129,318.61. This trade represents a 16.44% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Patrick J. Heron purchased 1,335 shares of the company’s stock in a transaction that occurred on Tuesday, March 4th. The stock was bought at an average price of $45.57 per share, for a total transaction of $60,835.95. Following the transaction, the director now directly owns 163,643 shares in the company, valued at $7,457,211.51. This trade represents a 0.82% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have sold 92,764 shares of company stock valued at $4,109,161 in the last ninety days. Insiders own 14.36% of the company’s stock.

Analyst Ratings Changes

Several analysts have recently weighed in on MIRM shares. JMP Securities increased their price target on shares of Mirum Pharmaceuticals from $74.00 to $76.00 and gave the company a “market outperform” rating in a research note on Friday, May 9th. Robert W. Baird lifted their target price on Mirum Pharmaceuticals from $50.00 to $55.00 and gave the company an “outperform” rating in a research report on Thursday, February 27th. Raymond James reiterated a “strong-buy” rating on shares of Mirum Pharmaceuticals in a report on Tuesday, May 13th. Finally, HC Wainwright reissued a “buy” rating and set a $73.00 price objective on shares of Mirum Pharmaceuticals in a research report on Monday, May 19th. Ten investment analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus target price of $60.73.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.